explore -WSS

explore

author：explore 2025-10-02 20:06:34 - browse：513

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： The EU Joint Clinical Assessment needs to live up to its promise

leisure time

hotspot

WSS

STAT Summit: Biotech founders on deal

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Beam Therapeutics to lay off 20% of its staff, re

Beam Therapeutics to lay off 20% of its staff, re

Man killed during FBI raid in connection with threats against Biden, other officials

UnitedHealth’s board chair also owns a personal investment firm

focus

explore

explore

Sports medicine is finally prioritizing gender equality

STAT Readout Newsletter: Today's biggest biotech updates

Peter Hotez and the public health issue of online harassment

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Medicare proposal to cover medical devices draws a mixed reaction

For Cytokinetics, FDA rejection of heart drug would help, not hinder

New air purifier tech could be key to improving indoor air quality

Emergent cuts jobs, executive role in business shake

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The EU Joint Clinical Assessment needs to live up to its promise

focus

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

2023 STAT Wunderkinds: get to know the winners

Police still searching for prisoner who escaped from NYC hospital

CEOs share strategies for surviving biotech slump

FDA warns J&J's Abiomed: We will regulate your software

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

leisure time

hotspot

hotspot

knowledge